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Abstract
Background:  The use of antidepressants during pregnancy has increased in recent years. In the
Netherlands, almost 2% of all pregnant women are exposed to antidepressants. Although guidelines have
been developed on considerations that should be taken into account, prescribing antidepressants during
pregnancy is still a subject of debate. Physicians and pharmacists may have opposing views on using
medication during pregnancy and may give contradictory advice on whether or not to take medication for
depression and anxiety disorders during pregnancy. In this study, we investigated information sources used
by general practitioners (GPs) and pharmacists and their common practices.
Methods: A questionnaire on the use of information sources and the general approach when managing
depression during pregnancy was sent out to 1400 health care professionals to assess information sources
on drug safety during pregnancy and also the factors that influence decision-making. The questionnaires
consisted predominantly of closed multiple-choice questions.
Results: A total of 130 GPs (19%) and 144 pharmacists (21%) responded. The most popular source of
information on the safety of drug use during pregnancy is the Dutch National Health Insurance System
Formulary, while a minority of respondents contacts the Dutch national Teratology Information Service
(TIS). The majority of GPs contact the pharmacy with questions concerning drug use during pregnancy.
There is no clear line with regard to treatment or consensus between GPs on the best therapeutic
strategy, nor do practitioners agree upon the drug of first choice. GPs have different views on stopping or
continuing antidepressants during pregnancy or applying alternative treatment options. The debate
appears to be ongoing as to whether or not specialised care for mother and child is indicated in cases of
gestational antidepressant use.
Conclusion: Primary health care workers are not univocal concerning therapy for pregnant women with
depression. Although more research is needed to account for all safety issues, local or national policies
are indispensable in order to avoid undesirable practices, such as giving contradictory advice. GPs and
pharmacists should address the subject during their regular pharmacotherapeutic consensus meetings,
preferably in collaboration with the TIS or other professionals in the field.
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Background
Pregnancy is a vulnerable period, also when it comes to
the adverse effects of drugs. Antidepressant use is increas-
ing, including among women who plan to become preg-
nant or are pregnant [1,2]. It is not known how primary
health care workers deal with the risks of treatment versus
the risks of the disease and what sources of information
they use on this topic. Treatment of depression and anxi-
ety may consist of psychotherapy, medication, electrocon-
vulsive therapy or a combination of several approaches.
General practitioners (GPs) treat 86% of the patients with
mental health problems themselves, and prescribe drugs
in most cases [3].
Doctors are confronted with a novel situation when a
patient becomes pregnant, a state in which all nonessen-
tial drugs should be avoided. However, pregnancy does
not prevent depression, and its prevalence is estimated at
between 14% and 20% [4].
Pharmacological treatment during pregnancy requires
fine balancing of risks and expected benefits in each indi-
vidual patient, taking the patients history, presentation
and preferences into account. The safety of antidepressant
use during pregnancy is still under debate since studies on
risks of major malformations, persistent pulmonary
hypertension and long term effects on neurodevelopment
report conflicting results [5-8]. On the other hand, stress
and depression are known to endanger both the mother
and pregnancy outcome, including abnormal behavioural
development of the infant at follow-up [9]. GPs are facing
the dilemma of whether or not to prescribe antidepres-
sants. They also have to consider other treatment options
such as psychological therapies which have been proven
to be effective in mildly to moderately depressed outpa-
tients[10] Because of its relatively low prevalence, it is dif-
ficult for each individual GP to gain experience in this
specific field. Therefore, it may be difficult for them to
deal with this dilemma when they are not able to find use-
ful information or apply the available data in practice
[11,12]. In the Netherlands 2% of all pregnant women use
antidepressants during pregnancy but another 2% stops
using them [1]. Although fluoxetine is one of the antide-
pressants with the most published experience and sertra-
line is considered to have the lowest placental passage,
pregnant women use all different kinds of antidepres-
sants, including the ones that have come on to the market
only recently [1].
We were interested in reasons for this variety in drug use.
The source of information is an important factor that
influences GPs' views on managing the mental health
problems of pregnant women [13]. Inconsistencies
between information sources may lead to contradictory
views and, as such, may give rise to confusion. For
instance, information from pharmaceutical companies is
cautious and restricted to the contents of the summary of
product characteristics (SPC), which mentions associa-
tions between antidepressant use during pregnancy and
the risk of pulmonary hypertension, cardiovascular birth
defects and neonatal withdrawal syndrome[14,15]. The
Dutch national Teratology Information Service (TIS),
which cites large database studies, reports that although
the increased risk of major congenital malformations has
to be considered, the absolute risk for individual patients
remains small. Poor neonatal adaptation – which is usu-
ally mild and transient – may occur. On the other hand, it
is not known whether fetal exposure to antidepressants
has long-term effects on behaviour and neurodevelop-
ment [9,16]. Finally, it is not known whether GPs follow
practical guidelines or use local policies.
The role of the pharmacist – as a guardian and adviser on
safe drug use during pregnancy – and the different sources
of information that he/she explores compared to GPs
have not been studied. We do not know whether GPs and
pharmacists are aware of the specific risks of using antide-
pressants during pregnancy or the risks of refraining from
medication, or whether they are acting accordingly.
It was the objective of this study to investigate where GPs
and pharmacists in the Netherlands obtain information
on the safety of gestational drug use and the pharmaco-
therapeutic approach when managing depression and
anxiety during pregnancy.
Methods
Context
The University Medical Center (UMC) Utrecht is involved
in a research project on the effects of antidepressants dur-
ing pregnancy. As part of this, we studied treatment poli-
cies of the main prescribers of antidepressants, the GPs,
and the reactions of pharmacists, who might intervene
when a pregnant patient comes to the pharmacy with a
prescription for an antidepressant. An inquiry was con-
ducted in a Dutch population of 700 randomly selected
GPs and 700 pharmacists. Permission of the ethics com-
mittee of the UMC Utrecht was not required to perform
the investigation.
Study design
We designed a questionnaire with items addressing poli-
cies in general practice in managing of depression and
anxiety during pregnancy and the sources of information
on this subject. We rated the participants' support for dif-
ferent pharmacotherapeutic approaches by referring to
possible treatment options such as stepping down medi-
cation or switching to another antidepressant. We also
inquired about their views on the first-choice antidepres-
sant during pregnancy and on the question whether spe-BMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
Page 3 of 9
(page number not for citation purposes)
cial care for the neonate is considered when
antidepressants are used until delivery. Answering the 20-
item questionnaire would take 15 minutes. The question-
naire and a pre-stamped return envelope were sent out by
mail. Randomly selected addresses of eligible GPs were
provided by NIVEL (Netherlands Institute for Health Serv-
ices Research). Pharmacists were extracted randomly from
members of the Royal Dutch Pharmaceutical Society
(KNMP). The study was conducted in 2006.
We analysed differences in sex and practice characteristics
between the two groups of respondents and compared
them to the Dutch population of health care workers in
the field.
Statistical analysis
We used descriptive analyses (frequencies and cross tabu-
lations). Differences between GPs and pharmacists were
tested using chi-square tests. We did not correct for multi-
ple testing. Data were analysed with SPSS, version 15.0.
Results
A total of 132 GPs and 144 pharmacists returned the ques-
tionnaires, resulting in a response rate of approximately
20%. The general characteristics of all participants are pre-
sented in Table 1 and 2. Demographical differences
between our sample and the entire Dutch population of
GPs and pharmacists were negligible. Nevertheless their
approach to treatment may differ.
Policy on "Depression and anxiety during pregnancy"
One of all GPs who responded had a local written policy
on the treatment of depression and anxiety during preg-
nancy which was available in the practice (Table 2). For
pharmacists, the results were comparable: although three
pharmacists stated they had a local written policy, only
one provided a copy. This particular policy recommended
stepping down medication if possible. It mentioned
fluoxetine and tricyclic antidepressants as the first choice,
and recommended neonatal observation during the first
two days after birth if drug use was continued until deliv-
ery.
Information sources used in pharmacotherapy during 
pregnancy
Table 3 lists information sources used by GPs and phar-
macists in decision-making and in advisory tasks when
dealing with pregnant patients. A few participants (among
both GPs and pharmacists) use standard works like Drugs
in Pregnancy and Lactation by Briggs, Freeman and Yaffe
[17]. Two thirds of GPs and a third of pharmacists never
consulted the national TIS, which is a significant differ-
ence (chi2 = 58.3; p < 0.001). Almost three quarters (72%)
of GPs regularly consult pharmacists for information on
drugs during pregnancy. Pharmacists, on the other hand,
would not consult a specialist such as a psychiatrist, who
is a specialist in the field. In the Netherlands, the reference
used most frequently by both pharmacists and GPs is the
"Pharmacotherapy Compass", the Dutch National Health
Insurance System Formulary, issued annually (in Dutch:
Farmacotherapeutisch Kompas, comparable to the Physi-
cians' Desk Reference in the US). The introductory para-
graph of each chapter discusses specific drug use during
pregnancy. Updates on research as well as information
provided by manufacturers are reviewed and followed by
Table 1: Characteristics of participating practitioners
General practitioners Pharmacists
Participants
(N = 130)
National
(N = 8,209)
Participants
(N = 144)
National
(N = 2,789)
Sex
Man % 63 66 53 54
Woman % 37 34 47 46
Practice
Solo % 33 25 ne ne
Duo % 33 30 ne ne
Group % 34 45 ne ne
Patients
M e a n n 2 7 5 84 2 8 39 1 4 88 3 0 0
SD n 1087 ne 3598 ne
Working experience in same practice (years)
1–5 % 20 ne 26 ne
6–10 % 27 ne 30 ne
11–20 % 22 ne 28 ne
21–35 % 32 ne 15 ne
ne = not estimatedBMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
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recommendations. The majority of the GPs (85%) rely on
the information of the Farmacotherapeutisch Kompas.
Guidelines issued by the Dutch College of General Practi-
tioners (NHG) – known as NHG standards – are used to a
lesser extent. The NHG standard on the treatment of
depression does not mention pregnancy, and the standard
on pregnancy does not mention gestational depression
and anxiety. A quarter of GPs (26%) contact the manufac-
turer of a specific drug for information. Pharmacists turn
to the industry significantly more frequently (76%; chi2 =
71.2, p < 0.001). Forty-five percent of GPs and 49% of the
pharmacists use the internet to look for information on
scientific evidence or reports from consensus groups. One
Table 2: Characteristics of the practice of participating practitioners
General practitioners
(N = 130)
Pharmacists
(N = 144)
Significant difference between GPs and pharmacists?
Number of pregnant patients annually *
0–20 57 21
21–30 32 12
31–100 32 40
101–300 0 15
Unknown 9 56
Written policy on treatment of depression and anxiety during pregnancy ns
Yes 1 3
No 128 140
Unknown 0 1
Presented is the number of pregnant patients visiting the practice annually and the availability of a policy on treatment of depression and anxiety during 
pregnancy in the practice of participation practitioners.
*p < 0.01, ns = not significant
Table 3: Information sources used by professionals when applying medication during pregnancy.
General practitioners
(N = 128) %
Pharmacists
(N = 142) %
Significant 
difference 
between GPs 
and 
pharmacists?
Always Most of the 
time
Some-times Never Always Most of the 
time
Some-times Never
Standard works 
on drug use in 
pregnancy and 
lactation
12 5 9 1 03 4 9 4 n s
National 
Teratology 
Information 
Service
5 1 11 7 6 6 1 6 1 23 9 3 3 * *
Pharmacist for 
general 
practitioners/
psychiatrist for 
pharmacists
5 2 3 4 52 8 0 3 2 77 0 n s
National Health 
Insurance System 
Formulary
48 37 13 3 23 23 38 16 **
NHG-standards* 7 23 38 31 5 8 37 51 **
Manufacturer 0 5 21 74 6 7 63 24 **
Internet e.g. 
Pubmed or 
Medline (research 
reports, issued 
guidelines)
2 9 34 55 2 8 39 51 Ns
* Guidelines issued by the Dutch College of General Practitioners (NHG)
** p < 0.01
ns = not significant
nr = not relevant, item concerns 2 questions, one for each groupBMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
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out of five participants answered "yes" to the question of
whether the subject of "treatment of depression and anxi-
ety during pregnancy" has ever been covered during pro-
fessional education courses.
Views on the therapeutic management of depression and 
anxiety before and during pregnancy
The results show that GPs' opinions on how to manage
depression and anxiety during pregnancy were not univo-
cal (Table 4). One out of five GPs (21%) said they regu-
larly refer patients to a psychiatrist, while the others
sometimes or never do so. Some GPs (9%) state that they
sometimes advise terminating the pregnancy when
patients who use antidepressants become pregnant, which
was also the case for 4% of the pharmacists. Within the
professions, opinions on continuing medication, lower-
ing the dose or stepping down varied widely. The majority
of the respondents (92% of the GPs and 98% of the phar-
macists) never or occasionally advised the patient to sub-
stitute the antidepressant drug used for another one.
Table 4: Approach to female patients who use antidepressants.
General practitioners
(N = 130) %
Pharmacists
(N = 144) %
Significant 
difference
Always Most of the 
time
Some-times Never Always Most of the 
time
Some-times Never between GPs 
and 
pharmacists?
Advise to a patient who uses antidepressants and states being pregnant
Refer to a 
psychiatrist
6 1 5 5 02 9 7 9 3 94 5 *
Advise to 
terminate 
pregnancy
00 9 9 1 01 3 9 6 n s
Step down and 
stop 
antidepressant
13 52 27 7 4 24 52 19 **
Continue 
antidepressants at 
mild symptoms
1 8 52 40 1 13 47 40 ns
Continue 
antidepressants at 
severe symptoms
14 36 36 13 19 35 26 20 ns
Change the used 
antidepressant for 
another
0 2 64 34 1 7 75 17 **
Lower the dose 0 16 40 44 1 10 57 32 **
Psychotherapy 
instead of 
antidepressants
3 9 33 55 3 20 53 24 **
Advise to a patient who uses antidepressants and is planning to become pregnant
Refer to a 
psychiatrist
5 1 35 2 3 0 1 1 1 43 4 4 1 * *
Advise to 
postpone 
pregnancy
2 1 3 6 32 3 2 3 2 86 7 * *
Step down and 
stop 
antidepressant
10 52 32 6 6 30 49 15 **
Continue 
antidepressants at 
mild symptoms
1 9 45 45 2 7 54 37 ns
Continue 
antidepressants at 
severe symptoms
11 39 33 17 13 38 30 19 ns
Change the used 
antidepressant for 
another
0 4 62 34 2 8 71 20 *
L o w e r  t h e  d o s e 0 1 0 4 74 4 1 8 5 23 8 n s
Psychotherapy 
instead of 
antidepressants
6 6 44 44 5 25 55 15 **
Presented are the answers to the question what would be your advice to a patient who uses antidepressants and states that she is pregnant or is planning to 
become pregnant? * p < 0.05, ** p < 0.01, ns = not significantBMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
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Substituting psychotherapy for medication – in order to
prevent drug exposure to the child – was never advised by
55% of GPs and 24% of pharmacists; (chi2 = 30.2; p <
0.01). Advice given to women who intend to become
pregnant did not differ from advice given to pregnant
women.
Arguments in favour of treating pregnant women with 
antidepressants
Most participants agreed with the statement that the need
to treat maternal complaints with antidepressants out-
weighs possible drug-associated risks for the child (Table
5). Only 20% of GPs and 58% of pharmacists were aware
of the negative effects of depression and anxiety on a
child's development. On the other hand, only 4% of GPs
and 35% of pharmacists believed antidepressants are not
associated with an increase in the risk of birth defects.
Sometimes an unstable social environment was given as a
reason for not changing medication during pregnancy.
Some participants said that they lacked the experience or
background information for providing a proper answer
on this topic.
Arguments against treating pregnant women with 
antidepressants
Only a few participants considered maternal depression
and anxiety as such as causing no harm to the child, thus
antidepressants could be avoided in pregnancy (Table 5).
Most GPs and pharmacists mention possible negative
effects on the child as a reason to avoid antidepressants.
For one third of GPs and pharmacists a possible neonatal
withdrawal syndrome was the most important reason to
avoid antidepressants during pregnancy. The fact that
none of the antidepressants are registered for use during
pregnancy was a reason to avoid antidepressants for 30%
of GPs and for 18% of the pharmacists. Only 28% of GPs
and 13% of pharmacists believe that antidepressants
should be avoided because psychotherapy is just as effec-
tive as antidepressants.
First-choice antidepressant during pregnancy
Nine different compounds were mentioned as the antide-
pressant of first choice during pregnancy (Figure 1). Par-
oxetine and fluoxetine were mentioned most frequently
by GPs; fluoxetine was the favourite among pharmacists.
Almost 20% of the GPs answered "no antidepressant at
all" and another 20% stated they had no idea, or that they
had no idea because of the absence of guidelines. Their
reason for choosing a specific antidepressant was usually
based on the first choice of their local pharmacotherapeu-
tic consensus groups. Coming in second, they chose a
drug because it had the most evidence of being safe to use
during pregnancy. However, a minority of GPs (9%) and
5% of the pharmacists still consider St. John's wort to be
a good alternative; one out of four participants saw no
harm in using valerian during pregnancy (Table 6). There
Table 5: Reasons in favour of prescribing antidepressants during pregnancy and reasons against pharmacotherapy during pregnancy.
General practitioners
(N = 130) n
Pharmacists
(N = 144) n
Significant difference between GPs 
and pharmacists?
What are reasons for treating depression or 
anxiety during pregnancy with antidepressants?
Because the severeness of maternal complaints outweigh 
possible risks for the child.
124 116 ns
Because depression and anxiety may affect the child's 
neurological and behavioural development.
28 84 **
Because antidepressants do not increase the risk on birth 
defects
55 1 * *
Other 24 2 **
Not responded 11 24 ns
What may be the reasons for avoiding 
antidepressants during pregnancy?
Because depression and anxiety do not affect the course 
of pregnancy
13 20 ns
Because depression and anxiety do not influence the 
development of the child
12 7 ns
Because antidepressants may have negative effects on the 
unborn child
93 82 ns
Because antidepressants may cause withdrawal effects 
after birth
44 53 ns
Because antidepressants are not officially registered for 
use during pregnancy
39 26 ns
Because psychotherapy is as effective as are 
antidepressants
36 18 *
Other 9 0 ne
Not responded 17 34 ns
* p < 0.05, ** p < 0.01, ns = not significant, ne = not estimatedBMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
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were no significant differences between the two groups of
professionals.
Is special perinatal care necessary?
A total of 13% of the responding GPs and 7% of the phar-
macists did not believe that antidepressant use during
pregnancy created a situation in which mother and child
needed to receive special or additional perinatal attention
(chi2 = 13.1, p < 0.01). Another 36% of the GPs and 38%
of the pharmacists did not consider antidepressant use to
be an indication for delivery under the care of a gynaecol-
ogist (Table 7).
Discussion
We investigated the opinions of general phycicians and
their attitudes towards drug treatment of depression dur-
ing pregnancy. In medical practice the risks and benefits
of each individual patient will be weighed carefully, tak-
ing all other aspects such as psycho-social environment in
to account. That made it difficult to give general answers
to all the questions. Nevertheless, from the answers given
we still can draw some conclusions. [13]. Although indi-
cations for prescribing antidepressants in general practice
have been studied extensively and national as well as local
guidelines and policies are issued, no specific attention
has been given to pregnant women [18]. Considering the
number of pregnant women who visit GPs and pharma-
cists annually and the prevalence of antidepressant use
during pregnancy (2% to 8%), doctors and pharmacists
will be confronted with this subject a number of times
each year. They do not have a broad experience compared
to experts in the field, but are the ones who decide on anti-
depressant use. The long waiting lists for psychotherapy in
the Netherlands may influence a preference for pharma-
cotherapy.
Patients complain about receiving contradictory counsel-
ling, which appears to result from health care profession-
als using different sources of information [13]. Some
follow the advice of pharmaceutical companies not to pre-
scribe antidepressants to pregnant women or only when
the benefits outweigh the risks. Package inserts of some
antidepressants contain information about associations
between antidepressant use during pregnancy and the risk
of pulmonary hypertension, cardiovascular teratology
and neonatal withdrawal syndrome. At the same time the
national TIS may point out that antidepressant use during
pregnancy has not been consistently shown to signifi-
cantly increase the risk of major congenital malforma-
tions, they may warn of relapse of the illness and the
negative effects of maternal stress and depression on the
developing child, and may conclude that treatment
should not be discontinued without thorough considera-
tion. A total of 66% of GPs do not use this free national
service. It is also surprising that while GPs value pharma-
cists as professionals who can be consulted on drug use
during pregnancy, pharmacists in turn seldom consult
psychiatrists, who may be more experienced on the sub-
ject when it comes to medication for mental illness during
pregnancy.
From our results it can be concluded that there are large
differences in views on managing depression before and
during pregnancy. Extreme answers such as advising ter-
mination of the pregnancy or never switching to an anti-
depressant which is more likely to be safe in pregnancy
show that professionals lack knowledge on the subject. It
also may explain why such a varied pattern of antidepres-
sant use exists. Although St. John's wort is a powerful herb
with strong serotonergic effects, GPs and pharmacists are
not unanimously opposed to its gestational use. It is not
recommended during pregnancy since serotonin is not
only a neurotransmitter but also a growth factor for the
brain and other tissues [16]. Moreover the quality of
herbal drugs is not always standardised. Valerian should
also be used with caution. Hepatic failure during preg-
nancy as well as cytotoxic effects have been described [19].
When asked to consider the risks and benefits of antide-
pressant use during pregnancy, most but not all respond-
ers point out that although antidepressants may have
negative effects on the child, the consequences of the
mother's illness outweighs the possible risks. We failed to
inquire after the option of continuing antidepressants
when the mother had no symptoms. Most respondents
underestimate the powerful and lasting effects of psycho-
Table 6: Views on the question "Do you consider herbal drugs a safe alternative for use during pregnancy?"
General practitioners
(N = 128) %
Pharmacists
(N = 143) %
Significant difference between GPs and Pharmacists?
St. Johns worth
Yes 9 5 ns
No 91 95
Valerian
Yes 21 24 Ns
No 79 76
ns = not significantBMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
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therapy, and therefore deny patients a chance to cut down
on medication. Not all GPs and pharmacists share the
opinion that antidepressants could cause very serious
withdrawal effects, which is probably the reason why
more than a third of respondents think a delivery under
the care of a midwife or GP is appropriate, while others
acknowledge the need for carefully monitoring the baby
after birth. The patients who participated in our research
projects complain about receiving contradictory advice on
this subject, considering the fact that almost half of Dutch
mothers prefer to deliver at home [20].
Limitations
Response rates in studies inquiring into policies are often
disappointingly low, because in general practitioners give
priority to direct care rather than to participating in
research. The 20% response rate in this survey is in line
with this. The professionals who returned the question-
naire might be the ones who are most involved with the
subject. But then again, our conclusion that information
and guidelines should be made available would hold true
to an even greater extent. Part of our questions forced the
respondents to choose among universal statements with-
Views on first choice pharmacotherapy during pregnancy Figure 1
Views on first choice pharmacotherapy during pregnancy.
0 5 10 15 20 25 30 35 40
Don't know
No antidepressant at all
Continue current antidepressant
Clomipramine
Sertraline
Fluvoxamine
Mirtazapine
Venlafaxine
Amitriptyline
Citalopram
Fluoxetine
Paroxetine
Respondents [% ]
General practitioners
Pharmacists
Table 7: Views on the question "Do pregnant women who use antidepressants need special perinatal attention?"
General practitioners
(N = 130) % Pharmacists (N=144) %
Significant difference between 
GPs and pharmacists?
Are regularly monitoring of the child with 
ultrasound, blood levels of antidepressants 
or follow-up on mental status of the 
mother required?
Yes 79 92 *
No 13 7
Unknown 8 1
Is antidepressant use an indication for 
delivery in a hospital under the supervision 
of a specialist?
Yes 55 59 Ns
No 36 38
Unknown 9 3
* p < 0.05, ns = not significantBMC Health Services Research 2009, 9:119 http://www.biomedcentral.com/1472-6963/9/119
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out weighing individual nuances. Nevertheless the
answers revealed broadly deviating opinions.
Conclusion
The data presented reflect the views of individual GPs and
pharmacists on how to provide pregnant women with the
best treatment, since few had policies they could refer to.
Opinion pieces and literature reviews almost always end
by stating that when treating pregnant women with anti-
depressants, the expected positive effects must be weighed
against the risks. Doctors are then faced with a problem,
though, because they do not have easy access to informa-
tion on the safety and efficacy of antidepressants during
pregnancy, which they could use to make an evidence-
based decision. The more so, since most research data that
can be found on the internet do not cover the entire range
of possible short-term and long-term effects nor do they
account for additional risk factors such as smoking or
alcohol use. Therefore the Teratology Information Center
– which evaluates the latest reports and collaborates on
exposure studies – should be consulted more often, also
since they have counselling services available for individ-
ual cases. Also, pharmacists – who seem to be credited to
a great extent as being the ones to turn to when it comes
to use of medication during pregnancy – could play an
important role by initiating local policy meetings, provid-
ing easily accessible and interpretative information and
reviewing guidelines. Development and implementation
of clear policies will mean that pregnant women will no
longer be sent from pillar to post.
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